Probiotic supplement SMT04 for people with irritable bowel syndrome
Tests the probiotic supplement SMT04 in people with irritable bowel syndrome.
Key facts
- Who runs it
- Changi General Hospital
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Single-arm, Open-label Clinical Trial to Evaluate the Effect of SMT04 in Irritable Bowel Syndrome (IBS)
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 20 Mar 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- SMT04 (M3XTRA)
- Record updated
- 12 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome (IBS) with diarrhoea or mixed type, or with functional diarrhoea. They take the probiotic supplement SMT04 daily for 3 months.
- Age
- The criteria say 21 years to 70 years. The record's age limits say 21 Years to 55 Years.
- Sex
- Men and women can join.
- Disease stage
- IBS with diarrhoea (IBS-D) or mixed type (IBS-M), or functional diarrhoea, by the Rome-III definition. Belly pain or discomfort at least 3 days a month in the last 3 months, starting at least 6 months ago.
- Earlier treatment
- No prebiotics, probiotics, antibiotics or anti-inflammatory drugs in the last 2 weeks.
- Biomarker or test result
- A latest colonoscopy (camera check of the bowel) within 5 years showing nothing abnormal.
Main reasons for not taking part
- Inflammatory bowel disease, celiac disease, lactose intolerance, diabetes, thyroid problems, cancer, or autoimmune disease
- Past surgery on the small or large bowel, or removal of appendix, womb or gallbladder in the last 6 months
- Severe mental illness, or psychiatric drugs changed in the last 3 months
- Active infection when joining
- Pregnancy or breast-feeding
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male or female, aged from 21 years to 70 years old
- Meet the criteria of the Rome-III-definition of IBS with diarrhoea or mixed subtypes, or functional diarrhoea Rome-III-definition: Abdominal pain or abdominal discomfort on minimum of three days per month during the last three months, starting at least six months ago, and a minimum of two of the following criteria:; Improvement of symptoms after defecation; Start of symptoms in association with a change in stool frequency; Start of symptoms in association with a change in stool consistency Subtype of IBS-D which requires more than 25% of the participant's stools to be loose and less than 25% hard and lumpy; subtype of IBS-M which the participant's stools must be both hard and lumpy, as well as loose in consistency at least 25% of the time. Functional diarrhoea: The experience of loose or watery stools without pain occurring in at least 75% of bowel movements for at least three months over the last six months
- Have the latest negative colonoscopy result within five years
- Literate and can complete questionnaire
- Written informed consent is obtained
Who cannot take part
- Known inflammatory bowel disease, lactose intolerance or other malabsorption syndromes, celiac disease, diabetes mellitus, thyroid dysfunction, cancer, immunodeficiency, autoimmune diseases, severe hepatic or renal insufficiency, other explainable causes of abdominal pain, diarrhoea or constipation
- Known operations involving small intestines and large intestines; or history of appendectomy, hysterectomy, and cholecystectomy in last 6 months
- Known severe mental illnesses; unstable type or dose of psychiatric drugs within the last 3 months that will affect their judgement of study participation
- Evidence of active infection at the time of inclusion
- History of use of prebiotics, probiotics, antibiotic therapy or anti-inflammatory drugs within the last 2 weeks
- Known current pregnancy or breast-feeding female
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 55 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Probiotic supplements improve IBS symptoms through manipulation of the gut microbiota. Metabolites derived from microbiota metabolism and host-microbiota co-metabolism have an impact on host intracellular signalling pathways. Although probiotic supplements improve IBS symptoms, the precise composition of probiotics that can achieve optimal response remains unclear. SMT04 (M3XTRA, GenieBiome Limited, Hong Kong, China) is a novel product that is commercially available as a dietary supplement in Singapore. It consists of a patented probiotics blend of 5 probiotics (3 Bifidobacteria and 2 Streptococci with 12.5 billion CFU in 1 sachet). Probiotics preparation that included varying composition of Bifidobacteria and Streptococci strains had previously demonstrated efficacy in achieving symptom improvement in IBS patients. Streptococcus thermophilus, a component of the blended probiotics, significantly improved intestinal functional barrier in healthy subjects. Thus there is potential for SMT04, a dietary supplement, to be a treatment option for IBS patients. This is a multi-centered trial, all data and samples from the study sites will be pooled together for analysis.
The group in the trial
- SMT04 ArmTreatment being tested
Each subject will take 1 sachet of SMT04 daily for 3 months.
Treatment: SMT04 (M3XTRA)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Single-arm, Open-label Clinical Trial to Evaluate the Effect of SMT04 in Irritable Bowel Syndrome (IBS)
- Plain-language title
- Probiotic supplement SMT04 for people with irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06636513, who can take part
- Record updated
- 12 February 2025